Only the changes from baseline in hs‐CRP, a marker for cardiovascular disease (CVD) risk or acute inflammation, were mildly, but significantly, decreased in the MS‐20 group when compared to the placebo group. This evidence concerns the gene MAP3K14 and cardiovascular disorder.